Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: Observations with tandutinib

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 4, 2011, Pages 889-896

  Mathew, Paul ^a   Tannir, Nizar ^a   Tu, Shi Ming ^a   Wen, Sijin ^a   Guo, Charles C ^a   Marcott, Valerie ^a   Bekele, Benjamin Nebiyou ^a   Pagliaro, Lance ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Bone metastases; PDGF; Platelet derived growth factor; Prostate cancer; Tandutinib

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; GRANISETRON; IMATINIB; LOPERAMIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TANDUTINIB; TAXANE DERIVATIVE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG POTENCY; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOCYTE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RECEPTOR BLOCKING; SIDE EFFECT; THROMBOCYTOPENIA;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SURVIVAL RATE;

EID: 80054723103     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1567-2     Document Type: Article

References (31)

1. C-H Heldin B Westermark 1999 Mechanism of action and in vivo role of platelet-derived growth factor Physiol Rev 79 1283 1316 10508235 1:CAS:528:DyaK1MXmvVymtLY%3D (Pubitemid 29473317)
2. A Chott Z Sun D Morganstern, et al. 1999 Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor Am J Pathol 155 1271 1279 10514409 10.1016/S0002-9440(10)65229-7 1:CAS:528:DyaK1MXntFWmt7Y%3D (Pubitemid 29488934)
3. H Uehara SJ Kim T Karashima, et al. 2003 Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases J Natl Cancer Inst 95 458 570 12644539 10.1093/jnci/95.6.458 1:CAS:528:DC%2BD3sXisFCqs7w%3D
4. E Buchdunger CL Cioffi N Law, et al. 2000 ABL protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 295 139 145 10991971 1:CAS:528:DC%2BD3cXnt1ygur4%3D
5. SJ Kim H Uehara S Yazici, et al. 2006 Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer J Natl Cancer Inst 98 783 793 16757703 10.1093/jnci/djj211 1:CAS:528: DC%2BD28XmtlOhsL0%3D (Pubitemid 43983302)
6. P Mathew P Thall CD Bucana, et al. 2007 Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases Clin Cancer Res 13 5816 5824 17908974 10.1158/1078-0432. CCR-07-1269 1:CAS:528:DC%2BD2sXhtFSntLrK (Pubitemid 47583906)
7. CTEP/Investigator's Brochure MLN518, Edition 3 (2004) Millenium Pharmaceuticals, Inc., Cambridge, MA
8. A Pandey DL Volkots JM Seroogy, et al. 2002 Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family J Med Chem 45 3772 3793 12166950 10.1021/jm020143r 1:CAS:528:DC%2BD38XlsVyms70%3D (Pubitemid 34856116)
9. DJ DeAngelo RM Stone ML Heaney SD Nimer RL Paquette, et al. 2006 Phase I clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics Blood 108 3674 3681 16902153 10.1182/blood-2006-02-005702 1:CAS:528:DC%2BD28Xht1Kgs7%2FM (Pubitemid 44864544)
10. Fisher LD, Belle GV (1993) Biostatistics: a method for the health sciences. Wiley, New York
11. Snedecor GW, Cochran WG (eds) (1980) Statistical methods, 7th edn. Iowa State University Press, Ames
12. Hollander M, Wolfe DA (1979) Introduction to the theory of nonparametric statistics. Wiley, New York
13. EL Kaplan P Meier 1958 Nonparametric estimator from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
14. N Mantel 1966 Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 60 163 170
15. SPLUS 2000 (1988-2000) Insightful Corporation, Seattle, WA
16. P Mathew PF Thall D Jones, et al. 2004 Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular Phase I trial in androgen-independent prostate cancer J Clin Oncol 22 3323 3329 15310776 10.1200/JCO.2004.10.116 1:CAS:528:DC%2BD2cXpsVGrsb0%3D (Pubitemid 41103689)
17. Y-J Ko EJ Small F Kabbinavar, et al. 2001 A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer Clin Cancer Res 7 800 805 11309325 1:CAS:528:DC%2BD3MXjs1emu7g%3D (Pubitemid 32708713)
18. K Rao S Goodin MJ Levitt, et al. 2005 A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer Prostate 62 115 122 15389797 10.1002/pros.20130 1:CAS:528:DC%2BD2MXht12jtLw%3D (Pubitemid 40096777)
19. AM Lin BI Rini V Weinberg, et al. 2006 A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy BJU Int 98 763 769 16796694 10.1111/j.1464-410X.2006. 06396.x 1:CAS:528:DC%2BD28XhtFartb%2FO (Pubitemid 44368021)
20. GK Bajaj Z Zhang E Garrett-Mayer, et al. 2007 Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy Urology 69 526 531 17382158 10.1016/j.urology.2006.12.006 (Pubitemid 46428397)
21. P Mathew PF Thall S Wen, et al. 2008 Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leucocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer Br J Cancer 99 1426 1432 18841158 10.1038/sj.bjc.6604706 1:CAS:528:DC%2BD1cXhtlSktb%2FO
22. P Mathew LL Pisters CG Wood, et al. 2009 Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer J Urol 181 81 87 19012911 10.1016/j.juro.2008.09.006 1:CAS:528:DC%2BD1MXht1entr4%3D
23. S O'Sullivan D Naot K Callon, et al. 2007 Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms J Bone Miner Res 22 1679 1689 17663639 10.1359/jbmr.070719 (Pubitemid 351235134)
24. S Fitter AL Dewar P Kostakis LB To TP Hughes MM Roberts K Lynch B Vernon-Roberts ACW Zannettino 2008 Long term imatinib therapy promotes bone formation in CML patients Blood 111 2538 2547 18042796 10.1182/blood-2007-07- 104281 1:CAS:528:DC%2BD1cXivFakt74%3D
25. ®) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity Eur J Pharmacol 551 27 33 10.1016/j.ejphar.2006.09.007 (Pubitemid 44648069)
26. K Vandyke S Fitter AL Dewar TP Hughes ACW Zannettino 2010 Dysregulation of bone remodeling by imatinib mesylate Blood 115 766 774 19890095 10.1182/blood-2009-08-237404 1:CAS:528:DC%2BC3cXhs1Giur8%3D
27. N Brownlow M Vaid NJ Dibb 2008 Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro Leukemia 22 1452 1453 18185521 10.1038/sj.leu.2405085 1:CAS:528:DC%2BD1cXosFSms7w%3D (Pubitemid 352006094)
28. Logothetis CJ, Lin S-W Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer
29. K Pietras T Sjoblom K Rubin, et al. 2003 PDGF receptors as cancer drug targets Cancer Cell 3 439 443 12781361 10.1016/S1535-6108(03)00089-8 1:CAS:528:DC%2BD3sXktlyiurY%3D (Pubitemid 38340290)
30. J Yu C Ustach HC Kim 2003 Platelet-derived growth factor signaling and human cancer J Biochem Mol Biol 36 49 59 12542975 10.5483/BMBRep.2003.36.1.049 1:CAS:528:DC%2BD3sXhtV2isb8%3D (Pubitemid 36836256)
31. K Pietras J Pahler G Bergers D Hanahan 2008 Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting PLoS Med 5 e19 10.1371/journal.pmed.0050019 18232728 10.1371/journal.pmed.0050019 (Pubitemid 351198267)